Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

The Missing Factors in Patient Recruitment

Manchester-based Latium Enterprises Inc expands further into the health sector

MANCHESTER, England, Jan. 23, 2020 /PRNewswire/ -- Panacea Patient Recruitment Limited announced today it has been acquired by Latium Enterprises Inc, effective 3rd January 2020. "Latium are ideally placed to help us grow in the UK and US clinical trials markets over the coming years," says Brian Murray, Managing Director at Panacea. "It's an exhilarating time for us, with significant orders already placed." The Company employs doctors and nurses, leverages digital marketing and provides real-time reporting to its clients. The benefit of its service to clients is, trials that finish on time and come in on budget.

"It's globally recognised that adequate and timely patient recruitment is a significant factor in enabling pharmaceutical companies to get new medicines registered. Panacea has identified a considerable gap in the market," says Brian Kennedy, Group Chairman at Latium Enterprises Inc. "We offer Panacea all the support and strategic direction it needs to maximise the opportunity from financial and legal advice through to operations and marketing expertise."

For more information visit panaceapatientrecruitment.com.

About Panacea Patient Recruitment Limited: Panacea is a specialist patient recruitment service provider based in Manchester, UK. Its clients are pharmaceutical companies, contract research organisations and clinical investigators.


About Latium Enterprises Inc: Latium is a private equity group that seeks out strategic opportunities and hones high growth potential. They have been in business for the last 30 years. They have ownership in multiple sectors spanning across the UK and US.


Brian Murray Managing Director
Panacea Patient Recruitment Limited
O: +44-(0)161-854-1322
M: +44-(0)7956-345175

These press releases may also interest you

at 17:10
Bristol Myers Squibb and Acceleron Pharma Inc. today announced the U.S. Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt), the first and only erythroid maturation agent (EMA), for the treatment of anemia failing an...

at 17:05
North Bud Farms Inc. ("NORTHBUD" or the "Company") announces, further to its news release of March 13, 2020, that the Company's principal regulator, the Ontario Securities Commission (the "Commission"), granted a management cease trade order...

at 17:02
The Board of Directors and shareholders of Altitude International, Inc. have approved a name change to Altitude International Holdings, Inc. to better reflect the Company's newly established business structure. The Company has taken all required...

at 17:00
The "Membranes - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Membranes Market accounted for $4.96 billion in 2018 and is expected to reach $12.68 billion by 2027, growing at a CAGR of 11%...

at 17:00
The Government of Canada is working closely with businesses and manufacturers nationwide to provide healthcare workers with the equipment they need to protect themselves and care for Canadians across the country. Today, the Government of Canada...

at 16:54
Dell Technologies Inc. (the "Company" or "Dell Technologies") announced today the pricing of the previously announced private offering by two of its wholly-owned subsidiaries, Dell International L.L.C. and EMC Corporation, as co-issuers (the...

News published on 23 january 2020 at 06:00 and distributed by: